Table 1.
Effects of the short- and continuous-acting GLP-1R agonists (Adapted from reference [13])
| Short-acting | Continuous-acting | |
|---|---|---|
| Exenatide | Exenatide* | |
| Lixisenatide | Liraglutide | |
| Albiglutide | ||
| Dulaglutide | ||
| Semaglutide | ||
| Clinical effects | ||
| GLP-1R activation | Intermittent | Continuous |
| HbA1c reduction | + | ++ |
| FPG reduction | + | ++ |
| PPG reduction | ++ | + |
| Gastric emptying deceleration | ++ | ←→ |
| Body weight reduction | ++ | ++ |
| Blood pressure reduction | + | + |
| Hearth rate increase | ←→ | + |
Abbreviations: GLP-1R glucagon-like peptide-1 receptor, HbA 1c glycated haemoglobin, FPG fasting plasma glucose, PPG postprandial glucose.
*Exenatide once-weekly.